Selected data models

You must log in to select data models for download or further analysis.

66 Search results.
Relevance Rating New first Old first

CLL Follow-Up Treatments NCT00090051 BO17072 - Follow-Up Subsequent treatments for Chronic Lymphocytic Leukemia NCT00090051 BO17072

- 10/28/15 - 1 form, 4 itemgroups, 16 items, 1 language
Itemgroups: Subsequent treatments chemotherapy, Subsequent treatments radiotherapy, Surgery, Other treatment
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 BO17072

CLL Follow-Up Month 9 BO17072 NCT00090051 - Follow-Up Month 9 Chronic Lymphocytic Leukemia NCT00090051 BO17072

- 10/28/15 - 1 form, 8 itemgroups, 29 items, 1 language
Itemgroups: Bone marrow examination, Result of Bone marrow examination, Is bone marrow involved with CLL?, Tumor assessment, Indicator lesions, Non-indicator lesions, Liver and spleen examination, Response assessment
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 BO17072

CLL Concomitant Treatments BO17072 NCT00090051 - Concomitant Treatmants Chronic Lymphocytic Leukemia BO17072 NCT00090051

- 10/28/15 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: Concomitant Treatments
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072 Treatments given for an adverse event should be recorded on the appropriate “Adverse event” page. Treatments given for prophylaxis or treatment of abnormal laboratory values (e.g. blood cells, potassium supplements, etc.) should be recorded on this page. List any treatments continuing at screen or that have begun since screen (or medical procedures performed) that are not recorded on Adverse event pages.

CLL Follow-Up BO17072 NCT00090051 - Follow-Up Study completion Chronic Lymphocytic Leukemia BO17072 NCT00090051

- 10/28/15 - 1 form, 6 itemgroups, 24 items, 1 language
Itemgroups: Complete response confirmation, Bone marrow sampling for molecular response, Blood sampling for molecular response, Completion of follow-up period, Study completion, Survival visit
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 BO17072

CLL Pharmacokinetics BO17072 NCT00090051 - Pharmacokinetics Cycle 1 and 3 of Chronic lymphocytic leukemia NCT0090051

- 10/28/15 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Blood sampling for pharmacokinetics (Rituximab), Blood sampling for pharmacokinetics (Fludarabine and Cyclophosphamide)
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Unscheduled Lab BO17072 NCT00090051 - Unscheduled Laboratories of Chronic lymphocytic leukemia NCT0090051

- 10/28/15 - 1 form, 5 itemgroups, 33 items, 1 language
Itemgroups: Unscheduled laboratory analysis, Laboratory analysis, Hematology, Blood chemistry, Electrocytes
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Tumor assessment FCR vs FC BO17072 NCT00090051 - Tumor assessment of Chronic Lymphocytic Leukemia NCT00090051 BO17072

- 10/28/15 - 1 form, 10 itemgroups, 45 items, 1 language
Itemgroups: Tumor assessment at screening, Indicator lesions, Non-indicator lesions, Liver and spleen examination, Tumor assessment after Cycle 3 and 6, Indicator lesions , Non-indicator lesions , Liver and spleen examination after Cycle 3 and 6, Response assessment after Cycle 3, Response assessment after Cycle 6
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Cycle 3-6 FCR vs FC BO17072 NCT00090051 - Chemotherapy Cycle 3-6 of Chronic Lymphocytic Leukemia NCT00090051 BO17072

- 10/28/15 - 1 form, 8 itemgroups, 63 items, 1 language
Itemgroups: Administration of Rituximab, Administration of Rituximab, Day 1, Day 2, Administration of Fludarabine, Fludarabine Medication, Administration of Cyclophosphamide, Cyclophosphamide Medication
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Lab BO17072 NCT00090051 - Laboratories of Chronic lymphocytic leukemia NCT0090051

- 10/27/15 - 1 form, 12 itemgroups, 49 items, 1 language
Itemgroups: Laboratory analysis, Hematology, Coombs tests indirect/direct, Blood chemistry, Electrocytes, Lymphocyte immunophenotyping (local lab), Lymphocyte immunophenotyping (local lab), Blood sampling, Blood sampling, Bone marrow examination, Result of Bone marrow examination, Is bone marrow involved with CLL?
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

Eligibility Leukemia NCT02225275

- 9/23/15 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL); ODM derived from: https://clinicaltrials.gov/show/NCT02225275

CALGB-10501 Adverse Event (AE) Form NCT00513747

- 7/8/15 - 1 form, 4 itemgroups, 26 items, 1 language
Itemgroups: Header, Patient demographics, Adverse event report, EXPECTED ADVERSE EVENTS
CALGB-10501 Adverse Event (AE) Form NCT00513747 Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=33F76A98-AE8B-2E5F-E044-0003BA3F9857

CALGB-10501 Chronic Lymphocytic Leukemia (CLL) Immunophenotype Form NCT00513747

- 6/18/15 - 1 form, 5 itemgroups, 23 items, 1 language
Itemgroups: Header, Patient demographics, Immunophenotype, B-cell Lineage/T-cell Lineage/Myeloid Lineage/Stem cell/Other, Comments
CALGB-10501 Chronic Lymphocytic Leukemia (CLL) Immunophenotype Form NCT00513747 Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=340EF355-2CB3-21DF-E044-0003BA3F9857

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial